Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optive vs Systane Frequency of Use in Dry Eye
NCT00406510Phase 4
Key facts
- Status
- Completed
- Countries
- 1
- Sponsor
- Janssen Pharmaceutical
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, Small Molecules
- Conditions
- dry eye syndrome (DED)
01
Overview
Phase 4, randomised, single-blind trial in dry eye syndrome (DED) comparing Optive with Systane (2 arms). Primary endpoints: Frequency of Use of Eye Drops and Duration of Action. Status: completed.
02
Design
2 arms- Study design
- RandomizedSingle-blind
Optive
Patients receiving Optive eye drops
Systane
Patients receiving Systane eye drops
03
Who it enrols
Adult patients with mild to moderate dry eye symptoms (SESOD score 2-4) who are not using topical cyclosporine and have no active ocular diseases or allergies.
04
Endpoints
Primary
Frequency of Use of Eye Drops
Duration of Action
Beyond the preview
Go deeper on NCT00406510.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00406510.